Chloramphenicol Sodium Succinate
The sodium succinate ester prodrug of chloramphenicol is hydrolyzed in the body to release active chloramphenicol, suitable for intravenous administration when oral or ophthalmic routes are not feasible. It is used for serious infections such as bacterial meningitis in settings where alternatives are unavailable. Hematological monitoring is essential due to the risk of bone marrow suppression.
Peso molecular
445,2000 g/mol
TPSA
162,00 Ų
Mecanismo de acción
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Estructura 2D
Cite this structure
Embed this structure
SMILES
O=C([O-])CCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc([N+](=O)[O-])cc1.[Na+]
InChI
InChI=1S/C15H16Cl2N2O8.Na/c16-14(17)15(24)18-10(7-27-12(22)6-5-11(20)21)13(23)8-1-3-9(4-2-8)19(25)26;/h1-4,10,13-14,23H,5-7H2,(H,18,24)(H,20,21);/q;+1/p-1/t10-,13-;/m1./s1
Molecular Formula
C15H15Cl2N2NaO8
HBD / HBA
2 / 8
Enlaces Rotables
9
Átomos Pesados
28
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
The sodium succinate ester prodrug of chloramphenicol is hydrolyzed in the body to release active chloramphenicol, suitable for intravenous administration when oral or ophthalmic routes are not feasible. It is used for serious infections such as bacterial meningitis in settings where alternatives are unavailable. Hematological monitoring is essential due to the risk of bone marrow suppression.
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Yes, Chloramphenicol Sodium Succinate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200729. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 656833. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="chloramphenicol-sodium-succinate"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/chloramphenicol-sodium-succinate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/chloramphenicol-sodium-succinate/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/chloramphenicol-sodium-succinate/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="chloramphenicol-sodium-succinate"></drugfyi-drug>